Cargando…

Precision oncology: Artificial intelligence, circulating cell‐free DNA, and the minimally invasive detection of pancreatic cancer—A pilot study

BACKGROUND: Pancreatic cancer (PC) is among the most lethal cancers. The lack of effective tools for early detection results in late tumor detection and, consequently, high mortality rate. Precision oncology aims to develop targeted individual treatments based on advanced computational approaches of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahado‐Singh, Ray O., Turkoglu, Onur, Aydas, Buket, Vishweswaraiah, Sangeetha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587955/
https://www.ncbi.nlm.nih.gov/pubmed/37787018
http://dx.doi.org/10.1002/cam4.6604
_version_ 1785123474191155200
author Bahado‐Singh, Ray O.
Turkoglu, Onur
Aydas, Buket
Vishweswaraiah, Sangeetha
author_facet Bahado‐Singh, Ray O.
Turkoglu, Onur
Aydas, Buket
Vishweswaraiah, Sangeetha
author_sort Bahado‐Singh, Ray O.
collection PubMed
description BACKGROUND: Pancreatic cancer (PC) is among the most lethal cancers. The lack of effective tools for early detection results in late tumor detection and, consequently, high mortality rate. Precision oncology aims to develop targeted individual treatments based on advanced computational approaches of omics data. Biomarkers, such as global alteration of cytosine (CpG) methylation, can be pivotal for these objectives. In this study, we performed DNA methylation profiling of pancreatic cancer patients using circulating cell‐free DNA (cfDNA) and artificial intelligence (AI) including Deep Learning (DL) for minimally invasive detection to elucidate the epigenetic pathogenesis of PC. METHODS: The Illumina Infinium HD Assay was used for genome‐wide DNA methylation profiling of cfDNA in treatment‐naïve patients. Six AI algorithms were used to determine PC detection accuracy based on cytosine (CpG) methylation markers. Additional strategies for minimizing overfitting were employed. The molecular pathogenesis was interrogated using enrichment analysis. RESULTS: In total, we identified 4556 significantly differentially methylated CpGs (q‐value < 0.05; Bonferroni correction) in PC versus controls. Highly accurate PC detection was achieved with all 6 AI platforms (Area under the receiver operator characteristics curve [0.90–1.00]). For example, DL achieved AUC (95% CI): 1.00 (0.95–1.00), with a sensitivity and specificity of 100%. A separate modeling approach based on logistic regression‐based yielded an AUC (95% CI) 1.0 (1.0–1.0) with a sensitivity and specificity of 100% for PC detection. The top four biological pathways that were epigenetically altered in PC and are known to be linked with cancer are discussed. CONCLUSION: Using a minimally invasive approach, AI, and epigenetic analysis of circulating cfDNA, high predictive accuracy for PC was achieved. From a clinical perspective, our findings suggest that that early detection leading to improved overall survival may be achievable in the future.
format Online
Article
Text
id pubmed-10587955
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105879552023-10-21 Precision oncology: Artificial intelligence, circulating cell‐free DNA, and the minimally invasive detection of pancreatic cancer—A pilot study Bahado‐Singh, Ray O. Turkoglu, Onur Aydas, Buket Vishweswaraiah, Sangeetha Cancer Med RESEARCH ARTICLES BACKGROUND: Pancreatic cancer (PC) is among the most lethal cancers. The lack of effective tools for early detection results in late tumor detection and, consequently, high mortality rate. Precision oncology aims to develop targeted individual treatments based on advanced computational approaches of omics data. Biomarkers, such as global alteration of cytosine (CpG) methylation, can be pivotal for these objectives. In this study, we performed DNA methylation profiling of pancreatic cancer patients using circulating cell‐free DNA (cfDNA) and artificial intelligence (AI) including Deep Learning (DL) for minimally invasive detection to elucidate the epigenetic pathogenesis of PC. METHODS: The Illumina Infinium HD Assay was used for genome‐wide DNA methylation profiling of cfDNA in treatment‐naïve patients. Six AI algorithms were used to determine PC detection accuracy based on cytosine (CpG) methylation markers. Additional strategies for minimizing overfitting were employed. The molecular pathogenesis was interrogated using enrichment analysis. RESULTS: In total, we identified 4556 significantly differentially methylated CpGs (q‐value < 0.05; Bonferroni correction) in PC versus controls. Highly accurate PC detection was achieved with all 6 AI platforms (Area under the receiver operator characteristics curve [0.90–1.00]). For example, DL achieved AUC (95% CI): 1.00 (0.95–1.00), with a sensitivity and specificity of 100%. A separate modeling approach based on logistic regression‐based yielded an AUC (95% CI) 1.0 (1.0–1.0) with a sensitivity and specificity of 100% for PC detection. The top four biological pathways that were epigenetically altered in PC and are known to be linked with cancer are discussed. CONCLUSION: Using a minimally invasive approach, AI, and epigenetic analysis of circulating cfDNA, high predictive accuracy for PC was achieved. From a clinical perspective, our findings suggest that that early detection leading to improved overall survival may be achievable in the future. John Wiley and Sons Inc. 2023-10-03 /pmc/articles/PMC10587955/ /pubmed/37787018 http://dx.doi.org/10.1002/cam4.6604 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Bahado‐Singh, Ray O.
Turkoglu, Onur
Aydas, Buket
Vishweswaraiah, Sangeetha
Precision oncology: Artificial intelligence, circulating cell‐free DNA, and the minimally invasive detection of pancreatic cancer—A pilot study
title Precision oncology: Artificial intelligence, circulating cell‐free DNA, and the minimally invasive detection of pancreatic cancer—A pilot study
title_full Precision oncology: Artificial intelligence, circulating cell‐free DNA, and the minimally invasive detection of pancreatic cancer—A pilot study
title_fullStr Precision oncology: Artificial intelligence, circulating cell‐free DNA, and the minimally invasive detection of pancreatic cancer—A pilot study
title_full_unstemmed Precision oncology: Artificial intelligence, circulating cell‐free DNA, and the minimally invasive detection of pancreatic cancer—A pilot study
title_short Precision oncology: Artificial intelligence, circulating cell‐free DNA, and the minimally invasive detection of pancreatic cancer—A pilot study
title_sort precision oncology: artificial intelligence, circulating cell‐free dna, and the minimally invasive detection of pancreatic cancer—a pilot study
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587955/
https://www.ncbi.nlm.nih.gov/pubmed/37787018
http://dx.doi.org/10.1002/cam4.6604
work_keys_str_mv AT bahadosinghrayo precisiononcologyartificialintelligencecirculatingcellfreednaandtheminimallyinvasivedetectionofpancreaticcancerapilotstudy
AT turkogluonur precisiononcologyartificialintelligencecirculatingcellfreednaandtheminimallyinvasivedetectionofpancreaticcancerapilotstudy
AT aydasbuket precisiononcologyartificialintelligencecirculatingcellfreednaandtheminimallyinvasivedetectionofpancreaticcancerapilotstudy
AT vishweswaraiahsangeetha precisiononcologyartificialintelligencecirculatingcellfreednaandtheminimallyinvasivedetectionofpancreaticcancerapilotstudy